Skip to main content

Table 1 Cancer specific survival (CSS) and clinicopathological findings in 162 patients operated with radical nephrectomy for clear cell renal cell carcinoma; multivariate analysis

From: Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

 

Cancer specific survival (CSS)

 

HR

95% CI

p-value

PAI-1 expression

   

No or low (ref.)

   

Medium/High

2.92

1.15 - 4.87

0.020

TNM stage group

  

< 0.001

I ref.

   

II

2.52

0.75 - 7.56

8.74

III

2.99

1.11 - 7.56

0.030

IV

11.60

4.27 - 31.44

< 0.001

Microvessel Density

   

Low (ref.)

   

High

2.19

1.24 - 3.85

0.007

TSP-1

   

High (ref.)

   

Low

3.69

1.74 - 7.81

0.001

Nuclear grade

   

(1+2) (ref.)

   

(3+4)

1.29

0.76 - 2.18

0.341

Continuously coded

   

Tumour size

1.01

0.92 - 1.11

0.837